HER2-positive breast cancer has a distinctive biology, wherein amplification of the HER2 oncogene leads to a cascade of downstream effects. While in the past this distinctive biology was associated with a higher risk of recurrence and impaired long-term outcome, our current understanding of this ...
HER2‐positive breast cancerT‐DM1trastuzumabtucatinibBackground Brain metastases (BrM) incidence is 25% to 50% in women with advanced human epidermal growth factor receptor 2 (HER2)﹑ositive breast cancer. Radiation and surgery are currently the main local treatment approaches for central nervous ...
HER2-positivebreastcancer46her2阳性乳腺癌 系统标签: breastpositive乳腺癌trastuzumab阳性pertuzumab Series.thelancetPublishedonlineDecember6,2016http://dx.doi/10.1016/S0140-6736(16)32417-51Breastcancer2HER2-positivebreastcancerSibylleLoibl,LucaGianniAnti-HER2treatmentforHER2-positivebreastcancerhaschangedthenatural...
内容提示: Serieswww.thelancet.com Published online December 6, 2016 http://dx.doi.org/10.1016/S0140-6736(16)32417-5 1Breast cancer 2HER2-positive breast cancerSibylle Loibl, Luca GianniAnti-HER2 treatment for HER2-positive breast cancer has changed the natural biology of this disease. This ...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago....
Pertuzumab: new hope for patients with HER2-positive breast cancer Human epidermal growth factor receptor 2 (HER2) overexpression is detected in approximately 15% to 20% of all breast cancers (BCs). A revolutionary change ... M Capelan,L Pugliano,E De Azambuja,... - 《Annals of Oncology》...
Effective targeting of the human epidermal growth factor receptor 2 (HER2) has changed the natural history of HER2 overexpressing (HER2+) metastatic breast cancer. The initial success of trastuzumab improving time to progression and survival rates led to the clinical development of pertuzumab, ado-tra...
Breast cancer is the most frequently diagnosed cancer in females. Despite significant advances in the treatment of early breast cancer, 30% of patients go on to develop metastatic disease and recurrence. Approximately 20% of breast cancers are human epidermal growth factor receptor 2 (HER)-positive...
with metastaticHER2-positive breast cancer-aform of breast cancer that exhibits amplification of the gene encoding [...] chinese.eurekalert.org chinese.eurekalert.org 转移性人类上皮生长因子受体2(HER2)阳性乳腺癌——这是一种表现为人类上皮生长因子受体2(HER2)编码的基因扩增的乳腺癌——的病人常常出现肿...
Breast cancers are ER-positive, HER2-positive, or triple negative. The type of breast cancer you have determines the type of medication you take. Learn more from experts at WebMD.